| Symbol | ATRA |
|---|---|
| Name | ATARA BIOTHERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, California, 91320, United States |
| Telephone | +1 805 - 623-4211 |
| Fax | — |
| — | |
| Website | https://www.atarabio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The companys product candidates comprise Tab-cel, ATA188, and CAR T Programs. Additional info from NASDAQ: |
New Form DEF 14A - Atara Biotherapeutics, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001193125-26-177285 <b>Size:</b> 3 MB
Read moreLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA
Read moreAtara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Read moreATRA Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Atara Biotherapeutics, Inc. Securities Lawsuit -- The Gross Law Firm
Read moreAtara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Read moreATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
Read morePomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA
Read moreATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm
Read moreAtara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Read morePomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02822495 | Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus… | — | Epstein-Barr Virus (EBV) Infections | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06429800 | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participa… | Phase1 | Lupus Nephritis | Withdrawn | 2025-04-16 | 2025-04-16 | ClinicalTrials.gov |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr V… | Phase1 | Nasopharyngeal Carcinoma | Terminated | 2019-02-19 | 2021-08-19 | ClinicalTrials.gov |
| NCT01646645 | Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of … | Phase2 | Cytomegalovirus | Completed | 2012-07-13 | 2019-12-11 | ClinicalTrials.gov |
| NCT00620633 | Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukem… | Phase1 | Leukemia | Completed | 2008-02-08 | 2021-02-26 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ATA3219 | DRUG | Phase PHASE1 | Lupus Nephritis | WITHDRAWN | NCT06429800 |
| CAR T cells | BIOLOGICAL | Phase PHASE1 | Malignant Pleural Mesothelioma (MPM) | ACTIVE_NOT_RECRUITING | NCT04577326 |
| cyclophosphamide | DRUG | Phase PHASE1 | Malignant Pleural Mesothelioma (MPM) | ACTIVE_NOT_RECRUITING | NCT04577326 |
| Pembrolizumab | BIOLOGICAL | Phase PHASE1 | Nasopharyngeal Carcinoma | TERMINATED | NCT03769467 |
| Tabelecleucel | BIOLOGICAL | Phase PHASE1 | Nasopharyngeal Carcinoma | TERMINATED | NCT03769467 |
| Placebo | DRUG | Phase PHASE1 | Primary Progressive Multiple Sclerosis | TERMINATED | NCT03283826 |
| ATA188 | BIOLOGICAL | Phase PHASE1 | Primary Progressive Multiple Sclerosis | TERMINATED | NCT03283826 |
| Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs) | BIOLOGICAL | Preclinical | CMV Viremia | NO_LONGER_AVAILABLE | NCT03010332 |
| tabelecleucel | BIOLOGICAL | Preclinical | Epstein-Barr Virus (EBV) Infections | NO_LONGER_AVAILABLE | NCT02822495 |
| CMV-pp65 CTLs | BIOLOGICAL | Phase PHASE2 | Cytomegalovirus | COMPLETED | NCT01646645 |
| EBV-specific T cells (EBV-CTLs) | BIOLOGICAL | Phase PHASE2 | EBV-induced Lymphomas | COMPLETED | NCT01498484 |
| WT1-sensitized T cells | BIOLOGICAL | Phase PHASE1 | Leukemia | COMPLETED | NCT00620633 |
| Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) | BIOLOGICAL | Phase PHASE1 | EBV-induced Lymphomas | COMPLETED | NCT00002663 |